Lexicon Pharmaceuticals Inc (LXRX) Cotización

Charts will tell a different story soon

FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of December 20, 2024.

Chances are looking pretty slim though.
https://www.globenewswire.com/news-release/2024/10/31/2973110/0/en/Lexicon-Announces-Outcome-of-FDA-Advisory-Committee-for-Zynquista-sotagliflozin-as-an-Adjunct-to-Insulin-Therapy-for-Glycemic-Control-in-Adults-with-Type-1-Diabetes-and-Chronic-Kid.html

Nothing wrong with locking in some green. Ilike how the chart is setting up.

GL

Glad I sold my 20,000 shares yesterday instead of waiting until today 😅🙄😢. Maybe back in tomorrow...

Viatris Announces Exclusive Licensing Agreement with Lexicon Pharmaceuticals for Sotagliflozin in all Markets Outside of the U.S. and Europe
Viatris OUS Logo (PRNewsfoto/Viatris Inc.)
News provided by
Viatris Inc.
Oct 16, 2024, 16:34 ET

Share this article

Continues to Expand Viatris' Innovative Portfolio in Cardiovascular Diseases
Leverages Viatris' Unique Global Infrastructure and Expertise
Includes Opportunities to Leverage the Potential of Sotagliflozin to Additional Indications
PITTSBURGH, Oct. 16, 2024 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced it has entered into an exclusive licensing agreement with Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) for sotagliflozin in all markets outside of the United States and Europe.

https://www.prnewswire.com/news-releases/viatris-announces-exclusive-licensing-agreement-with-lexicon-pharmaceuticals-for-sotagliflozin-in-all-markets-outside-of-the-us-and-europe-302278473.html

LXRX 10/18/2024 2.50 C Thinking the call action will be very much in play. I'm thinking shorts will need to cover soon.

Just my opinion.

Shorts keep increasing positions! 27.45m short as of today!! Betting against the institutions who took massive ownership in Q2??? Betting against the AdCom????

News: New Secondary Analysis of Phase 3 Data Demonstrates Sotagliflozin Improves Time-In-Range (TIR) and Several Parameters of Glucose Control and Variability in Basal Insulin-Treated Type 2 Diabetes
September 10, 2024 08:00 ET
| Source: Lexicon Pharmaceuticals, Inc.
Share






Study results aligned with positive clinical trial outcomes for type 1 diabetes treatment with sotagliflozin

TIR measures approach target set by American Diabetes Association

Data to be presented at the 60th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Madrid, Spain and online

THE WOODLANDS, Texas, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that data from the SOTA-INS CGM Phase 3 randomized clinical trial demonstrated that once-daily dosing of sotagliflozin 400 mg improved time-in-range (TIR) and several continuous glucose monitoring (CGM) parameters, including glucose variability, in insulin-treated type 2 diabetes (T2D) patients. Researchers also observed positive trends with the once-daily dose of 200 mg. Study findings will be presented September 12th at the 60th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Madrid, Spain and online.

The objective of the SOTA-INS CGM study was to evaluate the effect of sotagliflozin on TIR as assessed by CGM in people with T2D. The primary sub-study endpoint was mean change in percentage of time spent within TIR (glucose 70-180 mg/dL [3.9-10.0 mmol/L]) over 24 hours for sotagliflozin 400 mg versus placebo.

The American Diabetes Association recommends a TIR target of at least 70% (17 hours) in people with type 1 diabetes (T1D) or T2D. In this study, sotagliflozin 200 mg and 400 mg once daily TIR (15.3 and 15.9 hours, respectively) approached the ADA target, with modest reductions in time-above-range (TAR) and mild increases in time-below-range (TBR).

Sotagliflozin has previously demonstrated glycemic efficacy and improvements in TIR as an adjunct to insulin therapy in people with T1D who participated in the inTandem clinical trial program.


https://www.globenewswire.com/news-release/2024/09/10/2943581/0/en/New-Secondary-Analysis-of-Phase-3-Data-Demonstrates-Sotagliflozin-Improves-Time-In-Range-TIR-and-Several-Parameters-of-Glucose-Control-and-Variability-in-Basal-Insulin-Treated-Type.html

LXRX under $2

Back under $2 again, printing 1.70's. Setting up for another swing.

LXRX under $2

Just may be an early Christmas. https://www.globenewswire.com/news-release/2024/07/16/2913701/0/en/Lexicon-Pharmaceuticals-Receives-December-20-2024-PDUFA-Goal-Date-for-Sotagliflozin-Type-1-Diabetes-NDA-Resubmission.html

LXRX under $2

Garbage

Interesting sales estimates for Sota.
Apr 30, 2024
Leerink initiated coverage of Lexicon with an Outperform rating and $5 price target. The firm believes Lexicon’s first-in-class dual SGLT1/2 inhibitor sotagliflozin could address unmet need across multiple indications with large market opportunities, including heart failure, hypertrophic cardiomyopathy and Type 1 diabetes with chronic kidney disease, which could collectively drive blockbuster sales. Inpefa’s U.S. launch in HF should benefit from several meaningful tailwinds, Leerink says. It forecasts peak U.S. sales of $1B for Inpefa in HF and peak U.S. sales of $325M for sotagliflozin in HCM in FY32. The firm also points out that Lexicon plans to resubmit Zynquista’s NDA filing by mid-2024, with an anticipated 6-month review. Leerink forecasts peak U.S. sales of $225M for Zynquista in T1D with CKD in FY32.

Almost added back in but want to see confirmation for bottom. Double bottoms can be tricky. But even so, long term I like this.

Zacks analysis.
https://www.zacks.com/stock/news/2256264/all-you-need-to-know-about-lexicon-lxrx-rating-upgrade-to-buy

Upgrading to buy while I'm watching for the gap to fill which may put this around 1.40's. We'll see. I think analysts are always late to the party but this report is actually pretty timely.

Quite the gap there if that's what you're looking at.

LXRX.......................................https://stockcharts.com/h-sc/ui?s=LXRX&p=W&b=5&g=0&id=p86431144783

Lexicon will resubmit an NDA for sotagliflozin for patients with type 1 diabetes and chronic kidney disease. Good news. FDA rejected an NDA for type 1 diabetes in 2019. Now they changed their mind but only for patients with T1D+CKD. According to today's company presentation, slide 10, this population makes 21% of adults with T1D, or ~357,000 patients. Not a big addition to current indication. However, it will be the first gliflozin approved for T1D. No competition.

Lexicon Announces Oversubscribed $250 Million Private Placement of Equity Securities

Earnings expected next Thursday, a miss or a hit? Revenue a hit imo.

Form 4 filed

200 July 2.5 calls @.88 . Be back soon !!!

INBS**** AS ALWAYS SUPER FAST COMPUTERS***WHALES***HEDGES FUNDS*** TRADERS MIGHT SURGE THE VOLUME AT A VERY HIGH FREQUENCY****


WITHIN MINUTES*****UPTREND

SEEMS SETTING UP NICELY FOR THAT

Still looking pretty good here. Did trim a few 2.38's thouigh. Not sure if we'll see a reset soon or not.

LXRX..........................https://stockcharts.com/h-sc/ui?s=LXRX&p=W&b=5&g=0&id=p86431144783

Another 4000. @1.76

Oops

I’m in today 9500 @1.49 1/23/24

Ready to see this rock and roll. Get the Christmas rally going!

https://www.inpefahcp.com/


Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company developing treatments for human disease. The company was founded in 1995 in The Woodlands, Texas under the name Lexicon Genetics, Incorporated by co-founders Professor Allan Bradley, FRS and Professor Bradley's postdoctoral fellow Arthur T Sands. Wikipedia
Stock price: LXRX (NASDAQ) $1.16 +0.01 (+1.32%)
Dec 6, 10:18?AM EST - Disclaimer
Headquarters: The Woodlands, TX
CEO: Lonnel Coats (Jul 7, 2014–)
Revenue: 324.1 million USD (2019)
Number of employees: 225 (2011)
Founded: 1995, The Woodlands, TX
Founder: Arthur T Sands
Subsidiaries: Lex-Gen Woodlands, L.P., Lexicon Pharmaceuticals (New Jersey), Inc
Product
https://www.lexpharma.com/

https://www.lexpharma.com/media-center/news

Insider buying... Director Philippe Amouyal's Strategic 200,000 Share Purchase in Lexicon Pharmaceuticals Inc

https://finance.yahoo.com/news/director-philippe-amouyals-strategic-200-060356510.html?guccounter=1&guce_referrer=aHR0cHM6Ly9maW52aXouY29tLw&guce_referrer_sig=AQAAAIoi6pMjBlhAAWCTqsgFDgJ_L3Mq27MaOD9VoCvqo193rq8IznDFhr2okgZCfdpTcOoOQpbq-htdQ0dRd_C7SPjLqq1-XLfxoxxNvrWLXCfYfWwGJkWm40NnRnChJ7IS-3NNjcnArKcxghtaIU9gZcRtqotAVRnZUPj9phWfJymM

LXRX new 52 week low

$LXRX. Looking good. See this in a week or 2.

JMHO.

LXRX................................https://stockcharts.com/h-sc/ui?s=LXRX&p=W&b=5&g=0&id=p86431144783

Looks like we saw a bottom here with this spike in volume

LXRX new 52 week low

Guess I wasn't watching the board here Monk. Have been watching the chart though and have been accumulating around 1.10' last week and added today.

Cheers

LXRX new 52 week low

LXRX new 52 week low

LXRX new 52 week low

LXRX new 52 week low

LXRX 1.70's. Watching.

$LXRX https://finance.yahoo.com/news/lexicon-announces-planned-advancement-lx9211-004500120.html
Conference call this morning...

Conference Call and Webcast Information

Lexicon management will hold a live conference call and webcast Monday, June 26, 2023, at 8:00 am ET / 7:00 am CT. The dial-in number for the conference call is 888-317-6003 and the conference ID for all callers is 7186279. The live webcast and replay may be accessed by visiting Lexicon’s website at www.lexpharma.com/events. An archived version of the webcast will be available on the website for 14 days.

Quite the boost for institutionals.
https://www.sec.gov/Archives/edgar/data/1062822/000119312523160877/d449914dsc13da.htm

Agree. Too easy here. So predictable they'd be doing an offering though. Easy peasy this one is.
Taking nibbles in the 2.50's. Should have sold more on the highs yesterday.

LXRX MIGHT NOT BE LOOKING BACK AGAN, FDA APPROVED DRUG AND ALL BIG PHARMA EYEING. MY OPINION *******
ONE PAID $260M FOR BACKING OUT, NOW LOOK AT LXRX

2.75 support. See how it holds, or not. Interesting sell off.

LXRX.........................https://stockcharts.com/h-sc/ui?s=LXRX&p=W&b=5&g=0&id=p86431144783

Hey there Glenn. This puppy has been excellent. Certainly one to keep an eye on.